Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.

about

Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen.

P2860

Q48125765-9E67CF5A-D7B7-4DA7-AC51-22A0E13B9771

P2860

Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.

Item

http://www.wikidata.org/entity/Q38649909

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.

@en

type

Item

label

Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.

@en

prefLabel

Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.

@en

P1476

Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes

@en

P2093

M V Trivedi

http://www.w3.org/2001/XMLSchema#string

R Bhat

http://www.w3.org/2001/XMLSchema#string

R D Crutchley

http://www.w3.org/2001/XMLSchema#string

P2860

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen

Current medical treatment of estrogen receptor-positive breast cancer

Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen

Cancer statistics, 2015

Steroid hormone receptors in breast cancer management.

Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer.

Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment.

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

P2888

tpj.2017.36

P304

201-208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1038/TPJ.2017.36

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

G Hwang

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090938409

http://www.w3.org/2001/XMLSchema#string

P698

28762370

http://www.w3.org/2001/XMLSchema#string

Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.

about

P2860

P2860

Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698